返回
S
Steven R. Feldman
Wake Forest University School of Medicine
102H指数
2.1K论文数
5.6W被引数
收录论文 497
发表时间
Response to Papp et al., “Efficacy and safety of ESK-001, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: 52-week results from the long-term Phase 2 study in patients who participated in the Phase 2 STRIDE study”对Papp et al., “ESK-001(一种高度选择性、口服别构TYK2抑制剂)在患有中重度斑块状银屑病患者中的有效性与安全性:长期第2阶段研究中参与第2阶段STRIDE研究的患者52周结果”的回应

